Adimab Sustainability Profile
Adimab, a leading biotechnology company headquartered in the United States, was founded in 2007 and has since established itself as a pioneer in the field of antibody discovery and development. With a strong operational presence in key regions across the US and Europe, Adimab focuses on providing innovative solutions for therapeutic antibody generation, utilising its proprietary platform to streamline the discovery process. The company’s core offerings include a robust suite of services that enable partners to develop high-quality monoclonal antibodies efficiently. Adimab's unique approach combines advanced technology with a deep understanding of immunology, positioning it as a trusted partner for pharmaceutical and biotechnology firms. Notable achievements include collaborations with major industry players, solidifying its reputation as a leader in the antibody discovery landscape.
DitchCarbon Score
How does Adimab's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Adimab's score of 8 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Adimab's reported carbon emissions
Adimab, headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Adimab may not have established formal commitments to reduce its carbon footprint or engage in industry-standard climate initiatives at this time. As the company operates within a sector increasingly focused on sustainability, it may benefit from developing and communicating clear climate commitments to align with industry best practices.
How Carbon Intensive is Adimab's Industry?
How Carbon Intensive is Adimab's Location?
Adimab's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Adimab has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
